Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Africa access: moving fast, outcome uncertain.

J S James

    AIDS Treatment News
    |August 14, 2002
    PubMed
    Summary

    Affordable HIV treatments are crucial for developing nations, yet access remains limited due to high drug costs. Pharmaceutical patent protections hinder the availability of life-saving HIV medications for those who need them most.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ability of palatable food consumption to buffer against the short- and long-term behavioral consequences of social defeat exposure during juvenility in rats.

    Physiology & behavior·2017
    Same author

    Effects of electroconvulsive seizures on depression-related behavior, memory and neurochemical changes in Wistar and Wistar-Kyoto rats.

    Progress in neuro-psychopharmacology & biological psychiatry·2014
    Same author

    The effects of rewarding ventral tegmental area stimulation and environmental enrichment on lipopolysaccharide-induced sickness behavior and cytokine expression in female rats.

    Brain research·2008
    Same author

    Behavioral and physiological effects of a single injection of rat interferon-alpha on male Sprague-Dawley rats: a long-term evaluation.

    Brain research·2006
    Same author

    Testosterone cream available at CPS; gel approved by FDA.

    AIDS treatment news·2003
    Same author

    Fluconazole: Pfizer asked to lower Africa price.

    AIDS treatment news·2003

    Area of Science:

    • Global Health
    • Pharmaceutical Policy
    • Infectious Disease Management

    Background:

    • Limited access to modern HIV treatment in developing countries, with fewer than 1 in 1000 individuals receiving care.
    • High drug pricing, often mirroring developed nations' costs despite low manufacturing expenses, creates a significant barrier.
    • Pharmaceutical companies' concerns regarding patent protection have historically impeded the development of affordable treatment options.

    Discussion:

    • The disparity in HIV treatment access highlights a critical global health inequity.
    • Patent laws, while intended to foster innovation, can inadvertently restrict access to essential medicines.
    • The economic model of drug pricing requires re-evaluation to address public health needs in low-resource settings.

    Key Insights:

    • Affordable HIV drug manufacturing is feasible, but market exclusivity prevents widespread access.
    • Patient access to essential HIV therapies is directly linked to drug pricing and intellectual property rights.
    • Urgent need for innovative solutions to overcome financial and legal barriers to HIV treatment.

    Outlook:

    • Exploring alternative pricing models and patent workarounds for essential medicines.
    • International collaboration to ensure equitable access to HIV/AIDS pharmaceuticals.
    • Potential for policy changes to balance pharmaceutical innovation with global public health imperatives.

    Related Experiment Videos